Wave life sciences announces proof-of-concept preclinical data for adar editing program in alpha-1 antitrypsin deficiency

First proof-of-concept in vivo data for rna editing using endogenous adar enzymes in alpha-1 antitrypsin deficiency
WVE Ratings Summary
WVE Quant Ranking